Efficacy of micafungin against deep-seated candidiasis in cyclophosphamide-induced immunosuppressed mice.
OBJECTIVE
We investigated the effects of fluconazole and micafungin for the therapy of deep-seated candidiasis in a cyclophosphamide-induced immunosuppressed mouse model.


METHODS
We used the experimental model of intraperitoneal fungal abscess caused by Candida albicans, as described previously.


CONCLUSIONS
Micafungin efficacy was equal to that of fluconazole in one-tenth dosage even in peritonitis. We also assessed the short-term (24 h) and long-term (8 days) therapeutic effects after the end of therapy. Although the therapeutic effect of fluconazole was similar to that of micafungin at 24 h after the end of therapy, the effect of micafungin was superior to that of fluconazole at 8 days after the end of therapy.
Ninomiya
Mochiyoshi
M
Department of Obstetrics and Gynecology, Gifu University Graduate School of Medicine, Gifu, Japan.
Mikamo
Hiroshige
H
Tanaka
Kaori
K
Watanabe
Kunitomo
K
Tamaya
Teruhiko
T
D000818:Animals; D000935:Antifungal Agents / Q000627:therapeutic use*; D002177:Candidiasis / Q000188:drug therapy* / Q000276:immunology; D003520:Cyclophosphamide / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D054714:Echinocandins; D005260:Female; D015725:Fluconazole / Q000627:therapeutic use; D016867:Immunocompromised Host; D007166:Immunosuppressive Agents / Q000494:pharmacology; D055666:Lipopeptides; D008074:Lipoproteins / Q000627:therapeutic use*; D000077551:Micafungin; D051379:Mice; D008813:Mice, Inbred ICR; D008826:Microbial Sensitivity Tests; D010456:Peptides, Cyclic / Q000627:therapeutic use*; D013047:Specific Pathogen-Free Organisms
D000935:Antifungal Agents; D054714:Echinocandins; D007166:Immunosuppressive Agents; D055666:Lipopeptides; D008074:Lipoproteins; D010456:Peptides, Cyclic; D003520:Cyclophosphamide; D015725:Fluconazole; D000077551:Micafungin